医药板块爆发，医疗ETF（159828）涨近2%，创业板医药ETF国泰（159377）涨超1%

Core Insights - The national organization for drug procurement in China is entering a deepening phase, emphasizing principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [1] - The 11th batch of centralized procurement rules has been significantly optimized, allowing medical institutions to select recognized brands and requiring lowest-priced companies to justify their pricing and commit to not pricing below cost [1] - This adjustment aims to curb vicious price competition and shift the industry focus from "price wars" to "value wars," benefiting leading companies with stable production capabilities and strong cost control [1] Industry Developments - The National Medical Insurance Administration has initiated price governance for "four same" drugs, standardizing prices for over 27,000 drug specifications, which is expected to further concentrate market share among high-quality leading enterprises [1] - There is an exploration of direct settlement of procurement and national negotiation drug consumables by the medical insurance fund, aiming to reduce the payment cycle for pharmaceutical companies from six months to under 30 days, significantly improving cash flow and overall operational efficiency in the industry [1] Investment Opportunities - Interested investors can consider exposure to the pharmaceutical sector through medical ETFs such as 159828 and the 20% fluctuation-capable ChiNext medical ETF Guotai (159377) [1]